Fig. 1From: B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemiaB7-H3 antigen expression rate on acute myeloid leukaemia (AML) tumour cell surfaces. Flow cytometry was used to detect B7-H3 expression on six AML tumour cells. In the figure, Control stands for control groupBack to article page